Processa Pharmaceuticals, Inc. (PCSA)

Processa Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	4.46	5.66	8.76	4.69	3.26	1.61
Research & Development	5.7	5.8	11.49	6.88	3.17	2.32
Other Operating Expenses	-0.19	0	7.27	0.57	8.7	0
Operating Expenses	9.98	11.46	27.53	12.13	15.14	3.94
Operating Income	-9.98	-11.46	-27.53	-12.13	-15.14	-3.94
Interest Expense / Income	0	0	0	0	0.28	0.04
Other Expense / Income	-0.15	-0.34	-0.1	-0.18	-0	-0.01
Pretax Income	-9.83	-11.12	-27.42	-11.96	-15.41	-3.96
Income Tax	0	0	0	-0.53	-1	-0.6
Net Income	-9.83	-11.12	-27.42	-11.43	-14.41	-3.36
Shares Outstanding (Basic)	2	1	1	1	0	0
Shares Outstanding (Diluted)	2	1	1	1	0	0
Shares Change	116.63%	62.83%	5.16%	104.27%	35.72%	3.63%
EPS (Basic)	-6.39	-8.48	-34.05	-15.00	-50.80	-14.00
EPS (Diluted)	-6.39	-8.48	-34.05	-15.00	-50.80	-14.00
Free Cash Flow	-8	-8.07	-9.61	-8.72	-3.14	-2.75
Free Cash Flow Per Share	-3.24	-6.15	-11.93	-11.38	-8.38	-9.95
EBITDA	-9.74	-11.04	-26.55	-11.08	-14.25	-3.05
Depreciation & Amortization	0.08	0.08	0.87	0.88	0.88	0.88
EBIT	-9.83	-11.12	-27.42	-11.96	-15.13	-3.92

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).